Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proxalutamide in metastatic castration-resistant prostate cancer
CTR20170177Phase 2Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of proxalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Kintor Pharmaceutical Limited. Started Aug 2017; status: completed.
02
Drugs
proxalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20170177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170177.